1. Blasenkarzinomsystemtherapie
    M. Haas et al, 2021, Der Urologe CrossRef
  2. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer
    David J. Einstein et al, 2019, Current Treatment Options in Oncology CrossRef
  3. Treatment of metastatic bladder cancer: current and historical aspects
    A. A. Rumyantsev, 2022, Meditsinskiy sovet = Medical Council CrossRef
  4. Assessing the prevalence and severity of cisplatin-induced nephrotoxicity in a minority- low socioeconomic population in the Bronx, New York
    M Bakri Hammami et al, 2024, Journal of Chemotherapy CrossRef
  5. Renal Toxicity Associated with Weekly Cisplatin and Gemcitabine Combination Therapy for Treatment of Advanced Biliary Tract Cancer
    Satoshi Kobayashi et al, 2014, Oncology CrossRef
  6. Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved Outcomes
    Megan Giles et al, 2023, Research and Reports in Urology CrossRef
  7. Aplicação intratumoral de cisplatina no tratamento de sarcóide periocular em equino
    RODRIGO RIBEIRO et al, 2022, Revista Colombiana de Ciencia Animal - RECIA CrossRef
  8. Eligibility Criteria for Different Platinum-Based Chemotherapy Regimens in Metastatic Urothelial Carcinoma
    Faisal Azam et al, 2024, Cureus CrossRef
  9. Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use
    A. A. Gritskevich et al, 2022, Meditsinskiy sovet = Medical Council CrossRef
  10. Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada
    Di Maria Jiang et al, 2020, Bladder Cancer CrossRef
  11. Advances in diagnosis and treatment of bladder cancer
    Antonio Lopez-Beltran et al, 2024, BMJ CrossRef
  12. Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy
    Richard T O'Dwyer et al, 2024, Future Oncology CrossRef
  13. Expression and clinicopathologic significance of HER2 and PD-L1 in high grade urothelial carcinoma of the urinary tract
    Peizi Li, 2024, International Journal of Clinical and Experimental Pathology CrossRef